Home LiteratureArticle Details
PMID: 19693095 Published · ppublish English Journal Article Review

Environment-mediated drug resistance: a major contributor to minimal residual disease.

Nature reviews. Cancer ·Vol. 9 ·No. 9 ·2009-09-00 ·Pages 665-74

Meads MB, Gatenby RA, Dalton WS

Abstract

Environment-mediated drug resistance is a form of de novo drug resistance that protects tumour cells from the initial effects of diverse therapies. Surviving foci of residual disease can then develop complex and permanent acquired resistance in response to the selective pressure of therapy. Recent evidence indicates that environment-mediated drug resistance arises from an adaptive, reciprocal signalling dialogue between tumour cells and the surrounding microenvironment. We propose that new therapeutic strategies targeting this interaction should be applied during initial treatment to prevent the emergence of acquired resistance.

MeSH Terms
Drug Resistance, Neoplasm Humans Neoplasm, Residual/pathology Neoplasms/drug therapy,pathology Signal Transduction/drug effects Stromal Cells/drug effects,pathology
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Meads Mark B
Department of Experimental Therapeutics and Oncologic Sciences, H. Lee Moffitt Cancer Center, Florida 33612, USA.
Gatenby Robert A
Dalton William S
References (108)
108 references, click to expand
  1. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.
    Eur J Haematol. 2007 Sep;79(3):240-3 PMID: 17655704
  2. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
    Clin Cancer Res. 2007 Apr 1;13(7):2128-35 PMID: 17404096
  3. Stromal gene expression predicts clinical outcome in breast cancer.
    Nat Med. 2008 May;14(5):518-27 PMID: 18438415
  4. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells.
    Cancer Res. 1996 Sep 15;56(18):4146-9 PMID: 8797583
  5. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
    J Clin Oncol. 2000 Jan;18(1):80-6 PMID: 10623696
  6. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction.
    Cancer Cell. 2004 Aug;6(2):159-70 PMID: 15324699
  7. Bystander elimination of antigen loss variants in established tumors.
    Nat Med. 2004 Mar;10(3):294-8 PMID: 14981514
  8. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
    J Exp Med. 2007 Jan 22;204(1):49-55 PMID: 17210731
  9. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
    J Clin Oncol. 2008 Dec 1;26(34):5610-7 PMID: 18981465
  10. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions.
    Cancer Res. 2004 May 1;64(9):3215-22 PMID: 15126362
  11. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.
    J Immunol. 2008 Feb 1;180(3):1545-55 PMID: 18209050
  12. Tumor stroma and regulation of cancer development.
    Annu Rev Pathol. 2006;1:119-50 PMID: 18039110
  13. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Clin Cancer Res. 2006 Sep 1;12(17):5055-63 PMID: 16951221
  14. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.
    Blood. 2008 Oct 1;112(7):2935-45 PMID: 18535198
  15. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
    Br J Haematol. 2007 Jan;136(2):269-75 PMID: 17233818
  16. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase.
    Cell Death Differ. 2006 Oct;13(10):1776-88 PMID: 16410797
  17. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.
    Cancer Res. 2008 Jun 1;68(11):4398-405 PMID: 18519702
  18. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis.
    Cancer Res. 2004 May 1;64(9):3191-7 PMID: 15126359
  19. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.
    Cell. 2005 May 6;121(3):335-48 PMID: 15882617
  20. Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma.
    Melanoma Res. 2007 Aug;17(4):215-23 PMID: 17625451
  21. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma.
    Melanoma Res. 2004 Feb;14(1):29-37 PMID: 15091191
  22. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
    Cancer Res. 2006 Feb 15;66(4):2338-45 PMID: 16489039
  23. Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method.
    Leukemia. 2004 Dec;18(12):1981-8 PMID: 15470488
  24. Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.
    PLoS One. 2008 Feb 13;3(2):e1592 PMID: 18270579
  25. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
    Clin Cancer Res. 2005 Nov 1;11(21):7851-60 PMID: 16278408
  26. Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27.
    J Biol Chem. 2005 Nov 4;280(44):37266-77 PMID: 16105842
  27. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.
    Cancer. 1999 Jan 1;85(1):134-44 PMID: 9921985
  28. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis.
    Clin Cancer Res. 2005 Apr 1;11(7):2540-6 PMID: 15814631
  29. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma.
    Blood. 2003 Apr 1;101(7):2775-83 PMID: 12517814
  30. Development and characterization of a melphalan-resistant human multiple myeloma cell line.
    Cancer Res. 1991 Feb 1;51(3):995-1002 PMID: 1988143
  31. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    N Engl J Med. 2008 Aug 28;359(9):906-17 PMID: 18753647
  32. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.
    J Natl Cancer Inst. 1993 Sep 1;85(17):1419-24 PMID: 7688814
  33. Molecular characterization of the tumor microenvironment in breast cancer.
    Cancer Cell. 2004 Jul;6(1):17-32 PMID: 15261139
  34. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.
    Blood. 2001 Jan 15;97(2):346-51 PMID: 11154207
  35. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.
    Nat Med. 2003 Sep;9(9):1158-65 PMID: 12897778
  36. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.
    Blood. 2007 Sep 1;110(5):1631-8 PMID: 17502456
  37. Co-evolution of tumor cells and their microenvironment.
    Trends Genet. 2009 Jan;25(1):30-8 PMID: 19054589
  38. A pooled analysis of bone marrow micrometastasis in breast cancer.
    N Engl J Med. 2005 Aug 25;353(8):793-802 PMID: 16120859
  39. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
    Blood. 2004 Sep 15;104(6):1825-32 PMID: 15161667
  40. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1.
    Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10026-31 PMID: 10944199
  41. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma.
    Hematol Oncol. 2009 Mar;27(1):17-22 PMID: 18668701
  42. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.
    Immunity. 1999 Jan;10(1):105-15 PMID: 10023775
  43. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.
    Br J Cancer. 2006 Jun 5;94(11):1621-6 PMID: 16705310
  44. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.
    J Immunol. 2002 Mar 1;168(5):2544-53 PMID: 11859150
  45. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells.
    Oncogene. 2003 Apr 24;22(16):2417-21 PMID: 12717418
  46. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
    Blood. 2000 Apr 15;95(8):2630-6 PMID: 10753844
  47. Overexpression of integrin beta1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2-dependent degradation of p27 via PI3K pathway.
    J Cell Biochem. 2007 Oct 15;102(3):704-18 PMID: 17407140
  48. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Clin Cancer Res. 2009 Jan 15;15(2):520-31 PMID: 19147757
  49. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Clin Cancer Res. 2008 Jun 1;14(11):3306-11 PMID: 18519757
  50. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
    Clin Cancer Res. 2004 Aug 15;10(16):5342-8 PMID: 15328170
  51. Stromal gene signatures in large-B-cell lymphomas.
    N Engl J Med. 2008 Nov 27;359(22):2313-23 PMID: 19038878
  52. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.
    Blood. 2001 Jan 15;97(2):483-9 PMID: 11154226
  53. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival.
    Leuk Lymphoma. 2008 Jan;49(1):134-48 PMID: 17926185
  54. Quantitative model for multiple levels of drug resistance in clinical tumors.
    Cancer Treat Rep. 1983 Oct;67(10):923-31 PMID: 6627236
  55. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Clin Cancer Res. 2007 Nov 1;13(21):6469-78 PMID: 17975159
  56. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis.
    Am J Hematol. 2006 Apr;81(4):227-35 PMID: 16550517
  57. Stimulation of bone formation in vitro and in rodents by statins.
    Science. 1999 Dec 3;286(5446):1946-9 PMID: 10583956
  58. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.
    J Histochem Cytochem. 2009 Mar;57(3):239-47 PMID: 19001640
  59. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.
    J Cell Biol. 1997 Apr 7;137(1):231-45 PMID: 9105051
  60. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein.
    Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3808-14 PMID: 14506175
  61. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Leukemia. 2003 Jun;17(6):1175-82 PMID: 12764386
  62. Disruption of fibronectin binding to the alpha 5 beta 1 integrin stimulates the expression of cyclin-dependent kinases and DNA synthesis through activation of extracellular signal-regulated kinase.
    J Biol Chem. 1998 Jan 16;273(3):1662-9 PMID: 9430710
  63. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
    J Clin Oncol. 2002 Apr 15;20(8):2005-16 PMID: 11956259
  64. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.
    Nat Med. 1996 Nov;2(11):1204-10 PMID: 8898746
  65. Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer.
    Anticancer Res. 2002 Mar-Apr;22(2B):1065-70 PMID: 12168902
  66. Treatment of acute lymphoblastic leukemia.
    N Engl J Med. 2006 Jan 12;354(2):166-78 PMID: 16407512
  67. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
    Blood. 1996 Jun 15;87(12):5251-6 PMID: 8652840
  68. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.
    Leukemia. 2004 Aug;18(8):1380-90 PMID: 15201848
  69. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells.
    Cancer Cell. 2003 Apr;3(4):377-86 PMID: 12726863
  70. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
    Leukemia. 2008 Feb;22(2):353-60 PMID: 17972943
  71. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
    Blood. 2005 Jan 15;105(2):821-6 PMID: 15388585
  72. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation.
    Endocrinology. 2003 Feb;144(2):681-92 PMID: 12538631
  73. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.
    Blood. 2009 Jul 16;114(3):619-29 PMID: 19443661
  74. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.
    Cancer Res. 2002 Apr 1;62(7):2162-8 PMID: 11929839
  75. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
    Blood. 1999 Mar 1;93(5):1658-67 PMID: 10029595
  76. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.
    Proc Natl Acad Sci U S A. 1990 Sep;87(17):6698-702 PMID: 2168554
  77. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
    Blood. 2007 Aug 15;110(4):1271-7 PMID: 17456722
  78. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
    Blood. 2005 Sep 1;106(5):1824-30 PMID: 15905192
  79. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.
    Blood. 2004 May 1;103(9):3503-10 PMID: 14670925
  80. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.
    J Natl Cancer Inst. 1996 Sep 18;88(18):1285-96 PMID: 8797768
  81. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).
    Oncogene. 2000 Sep 7;19(38):4319-27 PMID: 10980607
  82. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
    Clin Cancer Res. 2008 May 1;14(9):2519-26 PMID: 18451212
  83. Integrin inhibitors reaching the clinic.
    J Clin Oncol. 2007 May 1;25(13):1637-8 PMID: 17470853
  84. Integrins and cytokines activate nuclear transcription factor-kappaB in human neutrophils.
    J Biol Chem. 2004 Jan 23;279(4):2657-65 PMID: 14613935
  85. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Blood. 2009 Jun 11;113(24):6215-24 PMID: 18955566
  86. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.
    Nat Med. 2001 Jun;7(6):687-92 PMID: 11385505
  87. Addressing the role of cell adhesion in tumor cell dormancy.
    Cell Cycle. 2006 Aug;5(16):1756-9 PMID: 16880738
  88. Equilibrium between host and cancer caused by effector T cells killing tumor stroma.
    Cancer Res. 2008 Mar 1;68(5):1563-71 PMID: 18316622
  89. Increased beta1 integrin is associated with decreased survival in invasive breast cancer.
    Cancer Res. 2007 Jan 15;67(2):659-64 PMID: 17234776
  90. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes.
    Cancer Res. 2008 Apr 15;68(8):2717-25 PMID: 18413739
  91. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
    Cancer Res. 2003 Nov 15;63(22):7900-6 PMID: 14633719
  92. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.
    Nat Med. 1999 Jun;5(6):662-8 PMID: 10371505
  93. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
    Oncogene. 2005 Jun 23;24(27):4462-71 PMID: 15806155
  94. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.
    Blood. 2004 Oct 1;104(7):2149-54 PMID: 15138161
  95. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.
    Cancer Res. 2009 Feb 1;69(3):1009-15 PMID: 19155309
  96. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.
    Cell Signal. 2003 Mar;15(3):327-38 PMID: 12531431
  97. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.
    Blood. 2009 Jan 22;113(4):866-74 PMID: 18927435
  98. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
    Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33 PMID: 526911
  99. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury.
    Oncogene. 2006 Mar 2;25(9):1378-90 PMID: 16247454
  100. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.
    Science. 1990 Mar 23;247(4949 Pt 1):1457-61 PMID: 2108497
  101. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.
    Leukemia. 2007 Jan;21(1):158-63 PMID: 17096013
  102. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo.
    J Biol Chem. 2004 Nov 5;279(45):46764-71 PMID: 15304496
  103. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo.
    Cancer Res. 2006 Feb 1;66(3):1526-35 PMID: 16452209
  104. Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine.
    Biochem Biophys Res Commun. 2003 Nov 21;311(3):708-12 PMID: 14623330
  105. Status of minimal residual disease testing in childhood haematological malignancies.
    Br J Haematol. 2008 Nov;143(4):481-9 PMID: 18710378
  106. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
    Blood. 2006 Aug 1;108(3):1050-7 PMID: 16627760
  107. Ras GTPases: integrins' friends or foes?
    Nat Rev Mol Cell Biol. 2003 Oct;4(10):767-76 PMID: 14570053
  108. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Cancer Res. 2002 Sep 1;62(17):5019-26 PMID: 12208756
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2714
Published
2009-09-00
Epub
2009-00-20
Pages
665-74
Language
English
Region
England
NLM ID
101124168
Subset
IM
External Links
PubMed source DOI: 10.1038/nrc2714 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2